NDC 58063-797 - ALOXI
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 58063-797
- Package NDCs from labels
- 58063-797-25, 58063-797-99, 58063-797-37
- Manufacturer
- MGI PHARMA
- Effective date
- 2008-09-23
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| ALOXI - MGI PHARMA | MGI PHARMA | 2008-09-23 | HUMAN PRESCRIPTION DRUG LABEL WITH HIGHLIGHTS |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 58063-797-25 | ALOXI | 5 mL in 1 VIAL | INJECTION | 5 | 3 | |
| 58063-797-37 | ALOXI | 5 in 1 CARTON | INJECTION | 5 | 3 | |
| 58063-797-99 | ALOXI | 1.5 mL in 1 VIAL | INJECTION | 1.5 | 3 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| palonosetron hydrochloride | ACTIVE INGREDIENT | 23310D4I19 | ALOXI (PALONOSETRON HYDROCHLORIDE) INJECTION [MGI PHARMA] | 3 | |
| palonosetron | ACTIVE MOIETY | 5D06587D6R | ALOXI (PALONOSETRON HYDROCHLORIDE) INJECTION [MGI PHARMA] | 3 | |
| citrate buffer | INACTIVE INGREDIENT | ALOXI (PALONOSETRON HYDROCHLORIDE) INJECTION [MGI PHARMA] | 3 | ||
| disodium edetate | INACTIVE INGREDIENT | 7FLD91C86K | ALOXI (PALONOSETRON HYDROCHLORIDE) INJECTION [MGI PHARMA] | 3 | |
| mannitol | INACTIVE INGREDIENT | 3OWL53L36A | ALOXI (PALONOSETRON HYDROCHLORIDE) INJECTION [MGI PHARMA] | 3 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | ALOXI (PALONOSETRON HYDROCHLORIDE) INJECTION [MGI PHARMA] | 3 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Palonosetron | PALONOSETRON | BluePoint Laboratories | ee6f6f94-1ca7-481e-9909-b19ae64e80c2 | 2026-08-25 | Warnings, Adverse reactions | 1728055 |
| Palonosetron | PALONOSETRON HYDROCHLORIDE | BLuePoint Laboratories | bb2be46a-56f7-48b6-bb05-3c6b12c8b1ea | 2026-07-06 | Warnings, Adverse reactions | 1728055 |
| Palonosetron | PALONOSETRON | NorthStar Rx LLC | 689c953c-2120-2546-67a4-22bb34ba3330 | 2025-12-24 | Warnings, Adverse reactions | 1728055 |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Eugia US LLC | 42e2d437-0712-4e9c-9c2a-00093c406d62 | 2025-10-30 | Warnings, Adverse reactions | 1728055 |
| Palonosetron | PALONOSETRON HYDROCHLORIDE | Apotex Corp. | 4af600d1-0ab1-41c5-af2f-9dc24cf3c90e | 2025-06-09 | Warnings, Adverse reactions | 1728055 |
| posfrea | PALONOSETRON | Avyxa Pharma, LLC | 13a201ba-c86d-48c5-a0e1-a3e0b4e6a2a7 | 2025-04-29 | Warnings, Adverse reactions | 1728055 1728050 |
| Palonosetron | PALONOSETRON HYDROCHLORIDE | Apotex Corp. | 903d7aba-277e-6d28-4fee-fd2d605ab6a9 | 2025-01-02 | Warnings, Adverse reactions | 1728055 |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Sandoz Inc | aff1505c-8d34-46e6-9559-c5b112887875 | 2024-02-05 | Warnings, Adverse reactions | 1728055 |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Meitheal Pharmaceuticals Inc. | 11bb07b2-6530-45ab-a916-ba9dd3107fc3 | 2023-08-17 | Warnings, Adverse reactions | 1728055 |
| palonosetron hydrochloride | PALONOSETRON HYDROCHLORIDE | Cipla USA Inc. | 37e7ef89-fd77-44e0-9271-ae91f8822603 | 2022-01-13 | Warnings, Adverse reactions | 1728055 |
| Palonosetron | PALONOSETRON HYDROCHLORIDE | Qilu Pharmaceutical Co., Ltd. | 633abdc2-a942-4eb2-a0f8-f9f4e727211e | 2021-10-18 | Warnings, Adverse reactions | 1728055 1728050 |
| PALONOSETRON | PALONOSETRON | Fresenius Kabi USA, LLC | 9132366b-b808-46c9-b167-c1900bc116b3 | 2020-12-29 | Warnings, Adverse reactions | 1728055 |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Baxter Healthcare Corporation | 0f3bfe3d-75c8-42eb-84be-570f8e251fdd | 2020-09-15 | Warnings, Adverse reactions | 1728055 |
| Palonosetron | PALONOSETRON | Dr.Reddy's Laboratories Limited | 991b8452-852c-c55c-7b1b-e97c4964777a | 2020-08-30 | Warnings, Adverse reactions | 1728055 1728050 |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Mylan Institutional LLC | 0a781796-bb74-4c5f-8d26-9ce520b818f7 | 2020-06-09 | Warnings, Adverse reactions | 1728055 |
| palonosetron hydrochloride | PALONOSETRON HYDROCHLORIDE | Sagent Pharmaceuticals | 6e60d03d-eae6-4924-a507-e77ea077c1ab | 2020-04-28 | Warnings, Adverse reactions | 1728055 |
| Palonosetron Hydrochloride | PALONOSETRON HYDROCHLORIDE | Teva Parenteral Medicines, Inc. | 911783eb-91a8-4ef4-bd6f-809211e207d6 | 2020-04-01 | Warnings, Adverse reactions | 1728055 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.